Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifentrine in chronic obstructive pulmonary disease (“COPD”) at CHEST Annual Meeting (“CHEST”) on Monday, October 21, 2019 at 02:30 AM CDT.
